Text Size

Clinical Assessment of Patients With High Bone Mass Due to Mutation in Lrp5

This study has been completed.
Sponsor:
Information provided by:
Odense University Hospital
ClinicalTrials.gov Identifier:
NCT01199094
First received: September 9, 2010
Last updated: NA
Last verified: August 2010
History: No changes posted
  Purpose

The aim of the study is to describe patients with a high bone mass phenotype due to a mutation in the low density lipoprotein l receptor 5 gene (LRP5) and compare them with age and sex matched controls. Moreover, bone density and microarchitecture as well as markers of bone metabolism are evaluated


Condition
Osteopetrosis

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Clinical Assessment of Patients With High Bone Mass Due to Mutation in Low Density Lipoprotein l Receptor 5

Resource links provided by NLM:

MedlinePlus related topics: Bone Density
U.S. FDA Resources

Further study details as provided by Odense University Hospital:

Primary Outcome Measures:
  • Bone microarchitecture as assessed by high resolution quantitative computed tomography (HR-pQCT) [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    HR-pQCT is used to evaluate bone microarchitecture, i.e. bone trabeculae, cortical thickness and trabecular number. Aim is to test if the microarchitecture of these patients are different that observed in normal controls


Secondary Outcome Measures:
  • Changes in bone turnover markers [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Markers of bone resorption and formation are investigated.

  • Bone mineral density [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    DXA is used to evaluate bone mineral density at total hip, spine, whole body and forearm.


Biospecimen Retention:   Samples With DNA

Serum, plasma, DNA as well as fat and skin biopsies


Enrollment: 38
Study Start Date: January 2009
Study Completion Date: June 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patients with mutation in the Lrp5 gene
Patients known to have a mutation in Lrp5 known to be causing a high bone mass phenotype

Detailed Description:

Cases and controls are closely matched on age and sex and evaluated cross-sectionally.

Dual x-ray absorptiometry (DXA) and high resolution peripheral quantitative computed tomography (HR-pQCT) are used in order to evaluate bone density as well as microarchitecture. Bone turnover markers and body composition are also measured.

  Eligibility

Ages Eligible for Study:   8 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Case-control study on almost 40 individuals

Criteria

Inclusion Criteria:

  • Lrp5 mutation/ADOI

Exclusion Criteria:

  • Pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01199094

Locations
Denmark
Odense University Hospital, Osteoporosis Clinic
Odense, Denmark, 5000
Sponsors and Collaborators
Odense University Hospital
Investigators
Principal Investigator: Kim Brixen, Professor Odense University Hospital
  More Information

Publications:

Responsible Party: Kim Brixen, Professor, consultant, Odense University Hospital
ClinicalTrials.gov Identifier: NCT01199094     History of Changes
Other Study ID Numbers: LRP5-HBM
Study First Received: September 9, 2010
Last Updated: September 9, 2010
Health Authority: Denmark: Danish Dataprotection Agency

Keywords provided by Odense University Hospital:
low density lipoprotein receptor 5
high bone mass
autosomal dominant osteopetrosis type I
bone turnover markers

Additional relevant MeSH terms:
Osteopetrosis
Osteosclerosis
Osteochondrodysplasias
 Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases

ClinicalTrials.gov processed this record on June 17, 2013